PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Protein Folding and Misfolding: It's the Journey, Not the Destination
March 2015
CCR5 and HIV Infection
January 2015
HIV/AIDS: Pre-fusion Env Exposed
January 2015
HIV/AIDS: Slide to Enter
January 2015
Updating ModBase
January 2015
Power in Numbers
August 2014
Quorum Sensing: A Groovy New Component
August 2014
Bacterial CDI Toxins
June 2014
Immunity: One Antibody to Rule Them All
June 2014
Virology: A Bat Influenza Hemagglutinin
March 2014
Virology: Making Sensitive Magic
March 2014
Virology: Visualizing Cyanophage Assembly
March 2014
Virology: Zeroing in on HBV Egress
March 2014
Viroporins
March 2014
Cas4 Nuclease and Bacterial Immunity
February 2014
Microbial Pathogenesis: A GNAT from Pseudomonas
February 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Microbiome: The Dynamics of Infection
September 2013
Membrane Proteome: A Funnel-like Viroporin
August 2013
Infectious Diseases: A Pathogen Ubiquitin Ligase
May 2013
Infectious Diseases: A Shared Syringe
May 2013
Infectious Diseases: Determining the Essential Structome
May 2013
Infectious Diseases: Targeting Meningitis
May 2013
NDM-1 and Antibiotics
May 2013
Bacterial Hemophores
January 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Microbial Pathogenesis: NEAT Iron
January 2013
Membrane Proteome: Sphingolipid Synthesis Selectivity
December 2012
A signal sensing switch
September 2012
Gauging needle structure
July 2012
Anthrax Stealth Siderophores
June 2012
A Pseudomonas L-serine dehydrogenase
May 2012
Pilus Assembly Protein TadZ
April 2012
Making Lipopolysaccharide
January 2012
Superbugs and Antibiotic Resistance
December 2011
A change to resistance
November 2011
An effective and cooperative dimer
November 2011
The Perils of Protein Secretion
November 2011
Bacterial Armor
October 2011
Breaking down the defenses
September 2011
Moving some metal
August 2011
Capsid assembly in motion
April 2011
Know thy enemy … structurally
October 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Hemolysin BL
January 2010
Unusual cell division
October 2009
Anthrax evasion tactics
September 2009
Toxin-antitoxin VapBC-5
September 2009
Antibiotic target
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
You look familiar: the Type VI secretion system
June 2009
Unique SARS
April 2009
Anthrax stealth molecule
March 2009
A new class of bacterial E3 ubiquitination enzymes
January 2009
Antiviral evasion
October 2008
SARS connections
September 2008
SARS Coronavirus Nonstructural Protein 1
June 2008

Research Themes Infectious diseases

Lysostaphin

PSI-SGKB [doi:10.3942/psi_sgkb/fm_2009_7]
Featured System - July 2009
Short description: Antibiotics are one of the major triumphs of twentieth century science, but unfortunately, the bacteria are fighting back.

Antibiotics are one of the major triumphs of twentieth century science, but unfortunately, the bacteria are fighting back. Drug-resistant strains are continually emerging as bacteria evolve and share new methods to shield their antibiotic-sensitive machinery, or destroy antibiotics directly. Today, we are searching for new approaches to fight our microscopic enemies using the tools of structural and molecular biology.

Magic Bullets

As with much of the earliest work in antibiotic discovery, researchers at the NYSGXRC are looking to the microbial world for leads. They have recently solved the structure of lysostaphin from the bacterium Vibrio cholerae. Like lysozyme, the original magic bullet explored by Alexander Fleming, lysostaphin is an enzyme that attacks the cell walls of bacteria. These cell walls are composed of long strings of sugars and amino acids, which are then crosslinked into a tough network that encloses the cell. Lysozyme and lysostaphin break linkages in this peptidoglycan network, and the cells burst under their own internal pressure.

Targeted Attack

Lysostaphin is a specialized killer, however. The crosslinks in the peptidoglycan come in many varieties. In some bacteria, the links are formed directly between amino acids in the peptidoglycan strands. In Staphylococcus aureus, however, a strand of five glycine amino acids is used as the linker. This is the weak point that is targeted by lysostaphin--it binds to the peptidoglycan sheath and clips these glycine crosslinkers.

Battling Infection

Lysostaphin is currently being tested as a possible treatment for infections by Staphylococcus infections. This includes topical formulations for treatment of infected wounds, as well as systemic formulations used in combination with antibiotics. Lysostaphin has been shown to be effective against antibiotic-resistant forms of the bacteria. But as with all interactions with bacteria, there is still the potential that they will develop ways to overcome it. Already, strains have been discovered that are less susceptible to lysostaphin, strains that either build a gluey polysaccharide capsule that shields their peptidoglycan, or strains that fortify the linkers in their peptidoglycan. The battle continues...

The JSmol tab below displays an interactive JSmol.

VapBC-5 Toxin-Antitoxin (PDB entry 3dbo)

The toxin is shown in pink and the antitoxin is shown in blue. Three water molecules, shown here in turquoise, are bound in the presumed active site, coordinated by a cluster of acidic amino acids, shown here in brighter red. These are thought to be the sites that bind to magnesium in the active enzyme. Use the buttons below to display or hide the antitoxin.

References

  1. Ragumani, S., Kumaran, D., Burley, S. K. and Swaminathan, S. (2008) Crystal structure of a putative lysostaphin peptidase from Vibrio cholerae. Proteins 72, 1096-1103.
    Kumar, J. K. (2008) Lysostaphin: an antistaphylococcal agent. Appl. Microbiol. Biotechnol. 80, 555-561.

  2. Firczuk, M., Mucha, A. and Bochtler, M. (2006) Crystal structures of active LytM. J. Mol. Biol. 354, 578-590.

  3. Bochtler, M., Odintsov, S. G., Marcyjaniak, M. and Sabala, I. (2004) Similar active sites in lysostaphins and D-Ala-D-Ala metallopeptidases. Prot. Sci. 13, 854-861.

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health